Health
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products

A Decade-Long Commitment to the Treatment of Cancer
We have commemorated World Cancer Day. More

Egis Health and Prevention Days return to Kőbánya

On the Egis Health and Prevention Days in Kőbánya participants were provided information on their health status More

Egis Health and Prevention Days in Kőbánya have been a success

As Diamond Sponsor of the comprehensive nationwide health tests program (MÁESZ), our company considers the protection of health to be top priority. More

Egis: Committed to Support Healthcare Workers

Egis Pharmaceutical PLC is committed to support the safety of medical staff in the current pandemic situation.

More

The continuous operation of Egis is vital

The quality of life of millions depends on the availability of our medicines, as Egis sells the most boxes of medicine in Hungary. Hungarian doctors most often choose Egis medicines particularly for the therapy of cardiovascular diseases, which is a common disease. Our medicines provide therapeutic solutions for the diseases cardiovascular diseases (38%), for the illnesses of the central nervous system (17%) and respiratory system (10%), further 10% are cancer treatment and immunotherapeutic drugs. Taking these medicines continuously is essential for maintaining the patients’ quality of life and for the success of the therapy.

More

Wash Your Hands the Right Way

WHO has created a six-step protocol: by applying this method, we can remove the germs, viruses, and bacteria from the surface of our hands.

More

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

More
Other channels
Egis World
Egis' products are sold to 100 countries.
Our People
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development
Corporate Social Responsibility
Healthcare and sharing knowledge are in the heart of our CSR activities
Events
Our highlighted past and future events you shouldn't miss

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox